Janux Therapeutics
JANX
216 hedge funds and large institutions have $3.43B invested in Janux Therapeutics in 2024 Q4 according to their latest regulatory filings, with 78 funds opening new positions, 80 increasing their positions, 43 reducing their positions, and 21 closing their positions.
271% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 21
233% more funds holding in top 10
Funds holding in top 10: 3 → 10 (+7)
91% more call options, than puts
Call options by funds: $37.7M | Put options by funds: $19.7M
86% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 43
66% more capital invested
Capital invested by funds: $2.07B → $3.43B (+$1.36B)
35% more funds holding
Funds holding: 160 → 216 (+56)
23.5% more ownership
Funds ownership: 87.46% → 110.97% (+24%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$63.5M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$59M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$55.5M |
| 4 |
Janus Henderson Group
London,
|
+$55M |
| 5 |
Holocene Advisors
New York
|
+$53.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$26.4M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$22M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$6.23M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$4.95M |
| 5 |
State Street
Boston,
Massachusetts
|
-$4.93M |
JANX Hedge Fund Activity: Q4 2024 in Review
216 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q4 2024, worth a combined $3.43B — up 66% from $2.07B a quarter earlier.
Buyers outnumbered sellers: 78 funds opened new JANX positions and 21 closed out — a net gain of 57 holders — while 80 added to existing stakes and 43 trimmed.
The largest buyer was RA Capital Management, adding an estimated $63.5M. The largest seller was OrbiMed, cutting an estimated $26.4M.
- 216 institutional investors held Janux Therapeutics (JANX) as of Q4 2024, up from 160 in Q3 2024.
- Funds reported $3.43B of Janux Therapeutics stock for Q4 2024, up 66% quarter-over-quarter.
- 78 funds opened new Janux Therapeutics positions in Q4 2024 and 21 closed out, a net change of +57 holders.
- The largest Janux Therapeutics buyer in Q4 2024 was RA Capital Management, an estimated $63.5M added.
- The largest Janux Therapeutics seller in Q4 2024 was OrbiMed, an estimated $26.4M sold.
Based on aggregated 13F filings for Q4 2024.